Company intelligence / Profile preview

Cyclarity Therapeutics

Novato, California, United Statescyclaritytx.com ↗
Ownership
Private
Development stage
Phase 1
01

Overview

Received regulatory approval to begin first-in-human clinical trial in January 2025. The trial will be conducted at CMAX in partnership with Monash University, led by Dr. Stephen Nicholls. The trial includes a traditional SAD/MAD phase 1 component plus enrollment of 12 patients with Acute Coronary Syndrome to assess safety and explore efficacy. All clinical trial material is manufactured and ready for administration, with all IND enabling studies completed successfully showing no predicted toxicological liabilities.

Therapeutic areas
OphthalmologyCardiovascularNeurology
Modalities
Custom-engineered cyclodextrins (polysaccharides)
Industry
Biotech
02

Drug pipeline

4 assets

UDP-003

1

3 more assets in the full pipeline.

Request access →
03

Partnerships

CMAXMonash UniversityVictorian Heart Institute (VHI)

Beyond the preview

Go deeper on Cyclarity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclarity Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call